Publications by authors named "Timothy Burn"

Claim this Profile
G
Global Expanded Access Program for Pemigatinib in Patients with Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma and Fibroblast Growth Factor Receptor Gene Alterations.
Anouk Lindley, Gerald Prager, Michael Bitzer, Timothy C Burn, Christine F Lihou

Cancer Res Treat· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential expression of C5aR1 and C5aR2 in innate and adaptive immune cells located in early skin lesions of bullous pemphigoid patients.
Shirin Emtenani, Maike M Holtsche, Richard Stahlkopf, Daniel L Seiler, Timothy Burn

Front Immunol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing.
Olaf Neumann, Timothy C Burn, Michael Allgäuer, Markus Ball, Martina Kirchner

Br J Cancer· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.
Daniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko, Sjors M Kas, Frank Rolfs, Timothy C Burn

Nature· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.
Daniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko, Sjors M Kas, Frank Rolfs, Timothy C Burn

Nature· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling.
Ian M Silverman, Meijuan Li, Karthikeyan Murugesan, Melanie A Krook, Milind M Javle, Timothy C Burn

J Mol Diagn· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor.
Liangxing Wu, Colin Zhang, Chunhong He, Dingquan Qian, Liang Lu, Timothy C Burn

J Med Chem· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinicogenomic Analysis of -Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib.
Ian M Silverman, Antoine Hollebecque, Luc Friboulet, Sherry Owens, Robert C Newton, Timothy C Burn

Cancer Discov· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.
Swamy Yeleswaram, Paul Smith, Timothy Burn, Maryanne Covington, Ashish Juvekar

Clin Immunol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nascent transcript and single-cell RNA-seq analysis defines the mechanism of action of the LSD1 inhibitor INCB059872 in myeloid leukemia.
Gretchen Johnston, Haley E Ramsey, Qi Liu, Jing Wang, Kristy R Stengel, Timothy Burn

Gene· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models.
Phillip C C Liu, Holly Koblish, Liangxing Wu, Kevin Bowman, Sharon Diamond, Timothy C Burn

PLoS One· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy.
Niu Shin, Matthew Stubbs, Holly Koblish, Eddy W Yue, Maxim Soloviev, Timothy Burn

J Pharmacol Exp Ther· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies.
Matthew C Stubbs, Timothy C Burn, Richard Sparks, Thomas Maduskuie, Sharon Diamond

Clin Cancer Res· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
INCB040093 Is a Novel PI3K Inhibitor for the Treatment of B Cell Lymphoid Malignancies.
Niu Shin, Yun-Long Li, Song Mei, Kathy He Wang, Leslie Hall, Timothy Burn

J Pharmacol Exp Ther· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.
Alessandro Maria Vannucchi, Srdan Verstovsek, Paola Guglielmelli, Martin Griesshammer, Timothy C Burn

Ann Hematol· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology.
Eddy W Yue, Richard Sparks, Padmaja Polam, Dilip Modi, Brent Douty, Timothy C Burn

ACS Med Chem Lett· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis.
John O Mascarenhas, Moshe Talpaz, Vikas Gupta, Lynda M Foltz, Michael R Savona, Timothy C Burn

Haematologica· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.
Michael Deininger, Jerald Radich, Timothy C Burn, Reid Huber, Dilan Paranagama

Blood· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I.
Ruben A Mesa, Srdan Verstovsek, Vikas Gupta, John O Mascarenhas, Ehab Atallah, Timothy Burn

Clin Lymphoma Myeloma Leuk· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: a putative mechanism for the onset of Wernicke's encephalopathy.
Qiang Zhang, Yan Zhang, Sharon Diamond, Jason Boer, Jennifer J Harris, Timothy Burn

Drug Metab Dispos· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of standards for quantitative assessment of JAK2 c.1849G>T (p.V617F) allele burden analysis in clinical samples.
Paul Collier, Keyur Patel, Paul Waeltz, Mark Rupar, Rajyalakshmi Luthra, Timothy C Burn

Genet Test Mol Biomarkers· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation.
Jordan S Fridman, Peggy A Scherle, Robert Collins, Timothy Burn, Claire L Neilan

J Invest Dermatol· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and characterization of INCB9471, an allosteric noncompetitive small-molecule antagonist of C-C chemokine receptor 5 with potent inhibitory activity against monocyte migration and HIV-1 infection.
Niu Shin, Kim Solomon, Naiming Zhou, Kathy He Wang, Vasudha Garlapati, Timothy Burn

J Pharmacol Exp Ther· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.
Jordan S Fridman, Peggy A Scherle, Robert Collins, Timothy C Burn, Yanlong Li

J Immunol· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phosphorylation State-Dependent High Throughput Screening of the c-Met Kinase.
Elham Behshad, Ronald M Klabe, Alexander Margulis, Mary Becker-Pasha, Mark J Rupar, Timothy C Burn

Curr Chem Genomics· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis